SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-008199
Filing Date
2017-02-07
Accepted
2017-02-07 06:44:35
Documents
2
Period of Report
2017-02-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6607
2 POA DOCUMENT poa.txt EX-24.4_699418 3286
  Complete submission text file 0001209191-17-008199.txt   11313
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Business Address
Flynn Peter D (Reporting) CIK: 0001586939 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33415 | Film No.: 17577176